Idiopathic Pulmonary Fibrosis
Effects of full-body exercise-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis protocol
BMJ Open. 2022 Dec 23;12(12):e064212. doi: 10.1136/bmjopen-2022-064212.
ABSTRACT
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterised by progressive and irreversible fibrosis of the lung parenchyma, resulting in reduced lung function. Since conventional medicines can be associated with low effective rates and adverse events, pulmonary rehabilitation may be a promising non-pharmacological therapy for IPF. Thus, we aimed to evaluate the effects of full-body exercise-based pulmonary rehabilitation on patients with IPF by conducting a systematic review and meta-analysis of randomised controlled trials (RCTs).
METHODS AND ANALYSIS: This systematic review and meta-analysis has been registered in the International Prospective Register of Systematic Reviews (PROSPERO). From inception to 31 August 2022, electronic databases in English and Chinese were searched, including PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials among the English databases. China National Knowledge Infrastructure, Chinese Biomedical Literature, VIP Chinese Science and Technology Periodical, and Wan Fang Data were among the Chinese databases. Two independent reviewers then screened the potential RCT studies, which were analysed according to the Cochrane Handbook criteria. The efficacy and safety of full-body exercise pulmonary rehabilitation for IPF were evaluated based on outcomes, including exercise capacity measured by 6 min walking distance and quality of life measured by St. George's Respiratory Questionnaire. Lung function was measured based on the forced vital capacity, total lung capacity, diffusing capacity of the lungs for carbon monoxide and dyspnoea assessed by the modified Medical Research Council scale.
ETHICS AND DISSEMINATION: Ethical approval was not required for this systematic review and meta-analysis. Results will be published in a peer-reviewed journal and presented at conferences.
PROSPERO REGISTRATION NUMBER: CRD42021284293.
PMID:36564122 | DOI:10.1136/bmjopen-2022-064212
Analysis of the Potential Relationship between Aging and Pulmonary Fibrosis Based on Transcriptome
Life (Basel). 2022 Nov 23;12(12):1961. doi: 10.3390/life12121961.
NO ABSTRACT
PMID:36556326 | DOI:10.3390/life12121961
Malignancies in Patients with Interstitial Lung Diseases: A Single Center Observational Study
J Clin Med. 2022 Dec 9;11(24):7321. doi: 10.3390/jcm11247321.
NO ABSTRACT
PMID:36555938 | DOI:10.3390/jcm11247321
Radiological Assessment in Idiopathic Pulmonary Fibrosis (IPF) Patients According to MUC5B Polymorphism
Int J Mol Sci. 2022 Dec 14;23(24):15890. doi: 10.3390/ijms232415890.
NO ABSTRACT
PMID:36555528 | DOI:10.3390/ijms232415890
Preferred Migration of Mitochondria toward Cells and Tissues with Mitochondrial Damage
Int J Mol Sci. 2022 Dec 12;23(24):15734. doi: 10.3390/ijms232415734.
NO ABSTRACT
PMID:36555376 | DOI:10.3390/ijms232415734
TRIB3 Mediates Fibroblast Activation and Fibrosis though Interaction with ATF4 in IPF
Int J Mol Sci. 2022 Dec 11;23(24):15705. doi: 10.3390/ijms232415705.
NO ABSTRACT
PMID:36555349 | DOI:10.3390/ijms232415705
Prognosis and Survival in Idiopathic Pulmonary Fibrosis in the Era of Antifibrotic Therapy in Italy: Evidence from a Longitudinal Population Study Based on Healthcare Utilization Databases
Int J Environ Res Public Health. 2022 Dec 12;19(24):16689. doi: 10.3390/ijerph192416689.
NO ABSTRACT
PMID:36554568 | DOI:10.3390/ijerph192416689
Pulmonary Fibrosis Related to Amiodarone-Is It a Standard Pathophysiological Pattern? A Case-Based Literature Review
Diagnostics (Basel). 2022 Dec 19;12(12):3217. doi: 10.3390/diagnostics12123217.
NO ABSTRACT
PMID:36553223 | DOI:10.3390/diagnostics12123217
Automated Classification of Idiopathic Pulmonary Fibrosis in Pathological Images Using Convolutional Neural Network and Generative Adversarial Networks
Diagnostics (Basel). 2022 Dec 16;12(12):3195. doi: 10.3390/diagnostics12123195.
NO ABSTRACT
PMID:36553202 | DOI:10.3390/diagnostics12123195
The Genetic and Epigenetic Footprint in Idiopathic Pulmonary Fibrosis and Familial Pulmonary Fibrosis: A State-of-the-Art Review
Diagnostics (Basel). 2022 Dec 9;12(12):3107. doi: 10.3390/diagnostics12123107.
NO ABSTRACT
PMID:36553114 | DOI:10.3390/diagnostics12123107
Genetics in Idiopathic Pulmonary Fibrosis: A Clinical Perspective
Diagnostics (Basel). 2022 Nov 23;12(12):2928. doi: 10.3390/diagnostics12122928.
NO ABSTRACT
PMID:36552935 | DOI:10.3390/diagnostics12122928
L-carnosine Attenuates Bleomycin-Induced Oxidative Stress via NFκB Pathway in the Pathogenesis of Pulmonary Fibrosis
Antioxidants (Basel). 2022 Dec 14;11(12):2462. doi: 10.3390/antiox11122462.
NO ABSTRACT
PMID:36552670 | DOI:10.3390/antiox11122462
Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience
Biomedicines. 2022 Dec 12;10(12):3229. doi: 10.3390/biomedicines10123229.
NO ABSTRACT
PMID:36551989 | DOI:10.3390/biomedicines10123229
The Role of the Microbiome in Connective-Tissue-Associated Interstitial Lung Disease and Pulmonary Vasculitis
Biomedicines. 2022 Dec 9;10(12):3195. doi: 10.3390/biomedicines10123195.
NO ABSTRACT
PMID:36551951 | DOI:10.3390/biomedicines10123195
Sexual Dimorphism in Interstitial Lung Disease
Biomedicines. 2022 Nov 24;10(12):3030. doi: 10.3390/biomedicines10123030.
NO ABSTRACT
PMID:36551792 | DOI:10.3390/biomedicines10123030
Lipidomic Profile Analysis of Lung Tissues Revealed Lipointoxication in Pulmonary Veno-Occlusive Disease
Biomolecules. 2022 Dec 14;12(12):1878. doi: 10.3390/biom12121878.
NO ABSTRACT
PMID:36551306 | DOI:10.3390/biom12121878
Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume
Respir Res. 2022 Dec 22;23(1):372. doi: 10.1186/s12931-022-02276-3.
NO ABSTRACT
PMID:36550474 | DOI:10.1186/s12931-022-02276-3
Interstitial lung disease progression after genomic usual interstitial pneumonia testing
Eur Respir J. 2022 Dec 22:2201245. doi: 10.1183/13993003.01245-2022. Online ahead of print.
NO ABSTRACT
PMID:36549706 | DOI:10.1183/13993003.01245-2022
Thymol protects against bleomycin-induced pulmonary fibrosis via abrogation of oxidative stress, inflammation, and modulation of miR-29a/TGF-β and PI3K/Akt signaling in mice
Life Sci. 2022 Dec 19:121256. doi: 10.1016/j.lfs.2022.121256. Online ahead of print.
NO ABSTRACT
PMID:36549352 | DOI:10.1016/j.lfs.2022.121256
The Idiopathic Pulmonary Fibrosis-Associated Single Nucleotide Polymorphism RS35705950 Is Transcribed in a MUC5B Promoter Associated Long Non-Coding RNA (AC061979.1)
Noncoding RNA. 2022 Dec 8;8(6):83. doi: 10.3390/ncrna8060083.
NO ABSTRACT
PMID:36548182 | DOI:10.3390/ncrna8060083